BR112016022463A2 - método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica - Google Patents

método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica

Info

Publication number
BR112016022463A2
BR112016022463A2 BR112016022463A BR112016022463A BR112016022463A2 BR 112016022463 A2 BR112016022463 A2 BR 112016022463A2 BR 112016022463 A BR112016022463 A BR 112016022463A BR 112016022463 A BR112016022463 A BR 112016022463A BR 112016022463 A2 BR112016022463 A2 BR 112016022463A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
immunogenic
inducing
immune response
individual
Prior art date
Application number
BR112016022463A
Other languages
English (en)
Portuguese (pt)
Inventor
Demoitie Marie-Ange
Renelle Donner Marie-Noelle
Ouaked Nadia
Theophile TEMMERMAN Stephane
Ripley Ballou William Jr
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112016022463A2 publication Critical patent/BR112016022463A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112016022463A 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica BR112016022463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
BR112016022463A2 true BR112016022463A2 (pt) 2017-10-10

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016022463A BR112016022463A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica
BR112016022787-5A BR112016022787A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112016022787-5A BR112016022787A2 (pt) 2014-04-02 2015-04-02 método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica

Country Status (18)

Country Link
US (3) US10688168B2 (https=)
EP (2) EP3125930B1 (https=)
JP (2) JP6645982B2 (https=)
KR (2) KR102762440B1 (https=)
CN (2) CN106456739A (https=)
AR (1) AR099960A1 (https=)
AU (1) AU2015239025B2 (https=)
BE (1) BE1022355B1 (https=)
BR (2) BR112016022463A2 (https=)
CA (2) CA2943711A1 (https=)
EA (1) EA037405B1 (https=)
ES (2) ES2961840T3 (https=)
GB (1) GB201405921D0 (https=)
IL (1) IL247493B (https=)
MX (3) MX2016012982A (https=)
SG (1) SG11201607086QA (https=)
WO (2) WO2015150568A1 (https=)
ZA (1) ZA201605955B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EA016648B1 (ru) 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
DK2457926T3 (da) * 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2731549C (en) * 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
AU2009273132B2 (en) * 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
BR112012018669A2 (pt) * 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10004793B2 (en) * 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
JP6655549B2 (ja) 2020-02-26
IL247493A0 (en) 2016-11-30
ES2853773T3 (es) 2021-09-17
WO2015150568A1 (en) 2015-10-08
EP3125930A1 (en) 2017-02-08
SG11201607086QA (en) 2016-09-29
US10624961B2 (en) 2020-04-21
CN106456738B (zh) 2021-06-29
BR112016022787A2 (pt) 2018-03-27
KR20230075525A (ko) 2023-05-31
AU2015239025A1 (en) 2016-09-22
MX2022013912A (es) 2022-12-13
CN106456739A (zh) 2017-02-22
BE1022355A1 (fr) 2016-02-16
US20170136110A1 (en) 2017-05-18
CN106456738A (zh) 2017-02-22
BE1022355B1 (fr) 2016-03-26
JP2017511324A (ja) 2017-04-20
EP3125929C0 (en) 2023-11-01
KR20160132115A (ko) 2016-11-16
US20170112914A1 (en) 2017-04-27
AU2015239025B2 (en) 2018-01-25
EA201691638A1 (ru) 2017-04-28
MX2016012932A (es) 2016-12-07
GB201405921D0 (en) 2014-05-14
ZA201605955B (en) 2019-04-24
EP3125929B8 (en) 2023-12-27
JP6645982B2 (ja) 2020-02-14
US20200306353A1 (en) 2020-10-01
MX2016012982A (es) 2016-12-07
EP3125929A1 (en) 2017-02-08
CA2943711A1 (en) 2015-10-08
WO2015150567A1 (en) 2015-10-08
US11951161B2 (en) 2024-04-09
KR102762440B1 (ko) 2025-02-03
EP3125930B1 (en) 2020-12-02
IL247493B (en) 2022-08-01
JP2017511327A (ja) 2017-04-20
EA037405B1 (ru) 2021-03-25
ES2961840T3 (es) 2024-03-14
US10688168B2 (en) 2020-06-23
CA2943007A1 (en) 2015-10-08
AR099960A1 (es) 2016-08-31
CA2943007C (en) 2024-01-09
EP3125929B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112016022463A2 (pt) método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
UY37523A (es) Anticuerpos anti-ox40 y sus usos
MX2018003491A (es) Represores de htt y usos de estos.
DOP2018000258A (es) Anticuerpos anti-cd40 y sus usos
BR112018012873A2 (pt) vacina de vírus zika
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
DK3244917T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
BR112017002183A2 (pt) conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
SV2018005624A (es) Anticuerpos anti-cd154 y metodos de uso de estos
DK3558391T3 (da) Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
DK3352783T3 (da) Vaccine omfattende immun-isolerede celler som producerer en immunmodulator
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements